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ABSTRACT
Osteosarcoma is the most common paediatric primary non-hematopoietic bone 
tumor; the survival is related to the response to chemotherapy and development 
of metastases. KMT2C is a chromatin-modifying and remodelling protein and its 
expression has never been studied in osteosarcoma. The aim of this study was to 
understand the role of KMT2C in the osteosarcoma carcinogenesis and metastatic 
progression to identify a new molecular target and to provide new therapeutic 
approach. 
We performed the immunohistochemical and gene expression analysis of 
KMT2C in 32 samples of patients with diagnosis of osteosarcoma with known clinic-
pathological data and we analysed the expression of genes involved in the metastatic 
pathway in four osteosarcoma cell lines by blocking the KMT2C expression using 
siRNA.
We found a nuclear-cytoplamic trafficking of KMT2C and the cytoplasmic 
localization was higher than the nuclear localization (p < 0.0001). Moreover, the 
percentage of cells with cytoplasmic positivity increased from low grade primary 
tissue to metastatic tissues. The cytoplasmic localization of KMT2C could lead to a 
change in its function supporting osteosarcoma carcinogenesis and progression. Our 
hypothesis is that KMT2C could affect the enhancer activity of genes influencing the 
invasive properties and metastatic potential of osteosarcoma.
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INTRODUCTION
Despite osteosarcoma being considered an 
uncommon cancer, it represents the primitive, non-
haematopoietic, malignant tumor of the bone that is 
commonly found [1–2]. Osteosarcoma arises mainly in 
the long bones of the extremities and the main feature is 
the detection of osteoid matrix produced by neoplastic 
cells [3]. The therapeutic protocols include neoadjuvant 
conventional chemotherapy, surgical resection of 
the primary tumor and post-operative chemotherapy 
[4]. Patients’ survival is related to the development 
of metastasis and the response to chemotherapy [5]. 
The 5-year survival rate for patients with osteosarcoma 
without evidence of metastasis is 60–65%, whereas it is 
only 20–28% for osteosarcoma patients with metastases 
at the time of diagnosis [6–7]. <90% of tumor necrosis 
evaluated on surgical specimen after neoadjuvant 
chemotherapy is considered a poor prognostic indicator 
(“non-responder” patients).
To date, clinical-pathological parameters and 
molecular markers that could be used as predictors 
of response to chemotherapy or to be able to identify 
patients with elevated risk of developing metastasis, have 
not yet been identified. Moreover, the molecular events 
causing development, progression and metastatic process 
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of osteosarcoma are still unknown [4, 8]. The somatic 
genome of the osteosarcoma is considered complex and 
characterized by tumor heterogeneity; indeed, increased 
number of mutations, structural and copy number 
variations and genomic instability are typical features of 
osteosarcoma. Moreover, the mutation rate of osteosarcoma 
is the highest among all pediatric tumors [9–10].
Therefore, the identification of genetic variations 
involved in osteosarcoma carcinogenesis and progression 
is a key point to understand the mechanisms that would 
allow the creation of personalized protocols, which 
could significantly increase treatment effectiveness and 
improve the outcomes. In our previous study of Whole 
Exome Sequencing (WES) analysis [11], we confirmed 
that the osteosarcoma karyotype is complex; indeed, 
we did not find a genetic variation common to all high-
grade osteosarcoma diagnostic biopsies analyzed, but we 
found that the KMT2C gene, a key component of histone 
H3 lysine 4 methyltransferase complexes [12], showed 
the highest number of variations in most of the samples 
being analyzed. It has been shown that highly conserved 
epigenetic regulators are frequently mutated in cancer and 
some studies suggest that variations in coding sequences of 
regulating elements, which act on enhancers to recognize 
specific transcriptional factors, may be the cause of tumor 
development [13]. Particularly, KMT2C acts together with 
hormone receptors and transcription factors involved in 
pathways that promote cell growth and performs its action 
in enhancer regions [12]. KMT2C is mutated in a wide 
spectrum of neoplasms, it has been linked to tumorigenesis 
[12], it has never been studied in osteosarcoma and its 
role in metastatic progression is unknown. KMT2C is 
implicated in the regulation of the TP53 gene [14], which 
encodes a tumor suppressor protein frequently altered 
in osteosarcoma [8]. Moreover, it has been shown that 
KMT2C mutations may alter its co-operation with the 
estrogen receptor [15] and this hormone plays a key role 
in bone development, remodeling and during matrix 
production [16]. Our earlier data showed that KMT2C 
could be involved in osteosarcoma carcinogenesis [11]. 
Therefore, the aim of this study was to confirm the role 
of KMT2C in the osteosarcoma carcinogenesis on a 
large cohort of osteosarcoma samples and evaluate it in 
osteosarcoma metastatic progression on osteosarcoma 
cell lines. The goal was to identify a molecular target 
to provide the basis for a new therapeutic approach and 
improve the survival of patients with osteosarcoma.
RESULTS
Immunohistochemical results
We evaluated the KMT2C immunohistochemical 
expression of 32 samples on Tissue MicroArray (TMA) 
sections and we observed that all osteosarcoma samples 
showed cytoplasmic expression of KMT2C and 31/32 
(97%) osteosarcoma samples also showed nuclear 
localization (Figures 1, 2).
The mean value of nuclear and cytoplasmic protein 
localization was 8.9 (range 0–80) and 38.6 (range 3–88) 
respectively. Only one sample did not show the nuclear 
localization of KMT2C; this was a patient with high-grade 
osteosarcoma of the femur (stage IIB), follow-up was 6 
years, he responded to neoadjuvant chemotherapy and did 
not develop metastasis. 
The average percentage of nuclear and cytoplasmic 
positive cells is described in Table 1. 
The normal bone tissue controls mainly showed 
a nuclear expression of KMT2C and occasionally a 
cytoplasmic protein localization. 
KMT2C mRNA expression
We observed that KMT2C was up-regulated and 
down-regulated in 84.4% (27/32) and 15.6% (5/32) 
of osteosarcoma samples respectively compared to 
osteoporosis tissue sample used as control. The results 
of KMT2C gene expression analysis are described in 
Table 1. We did not find a statistical association between 
KMT2C gene expression and clinical-pathologic features 
of patients or the cellular localization of the protein. 
Immunofluorescence protein localization in cell 
culture
The immunofluorescence was performed on 
confluent osteosarcoma culture cells and we found that 
KMT2C localized at both nuclear and cytoplasmic levels 
in all primary and metastatic cell lines analysed (Figure 3). 
Effective targeting of KMT2C with RNA 
interference
A duration of 24 and 48 hours after transfection with 
KMT2C siRNA, quantitative real-time PCR assay was 
performed to analyse the expression of KMT2C mRNA. 
The expression of KMT2C mRNA was suppressed in the 
groups transfected with KMT2C siRNA compared with 
the group without transfection (T0, Figure 4). All primary 
osteosarcoma cell lines showed an expression decrease 
of 97% (Figure 4A–4D) whereas the metastatic cell line 
Hs888 showed an expression decrease of 94% (Figure 4C). 
The expression of β-actin mRNA showed no change as an 
internal control.
Expression modulation of genes involved in the 
metastatic pathway after KMT2C silencing
Using Applied Biosystems™ Analysis Software, we 
analyzed 92 genes involved in metastatic pathway and 4 
housekeeping genes using mRNA of osteosarcoma cell 
lines before and after 24 h KMT2C siRNA transfection. 
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We found that of 4 housekeeping genes tested, HPRT1 
appeared as the most reliable control genes for the analysis 
of RealTime PCR data. 
We noted that 3 genes (3/92, 3.3%, CXCL12, 
SERPINE1 and HTATIP2) were upregulated only in 
metastatic cell line Hs888. 
After KMT2C siRNA transfection we observed 
that 8 genes (8/92, 8.7%, FN1, CD44, MMP2, TIMP1, 
CTNNA1, CXCL12, SERPINE1 and HTATIP2) showed 
different expression levels compared to the previously 
performed analysis (Table 2). 
We found that there was an upregulation of both 
CD44 and FN1 (except in the Saos-2 cell line) and 
following KMT2C mRNA silencing, cell lines 143B and 
MG63 showed an increase in FN1 expression levels and a 
decrease in CD44 levels while the Saos-2 and the Hs888 
metastatic line behaved in the opposite way. After KMT2C 
mRNA silencing, we observed an increase in expression 
levels of MMP2 in all four cell lines while TIMP1 levels 
decreased in all primary cell lines while it remained 
constant in metastatic cell line Hs888. We observed that 
MG63 cell line and Hs888 metastatic cell line showed an 
upregulation of gene codifying α-CATENIN (CTNNA1); 
following KMT2C mRNA silencing, CTNNA1 gene 
showed a lower gene expression value in the metastatic 
line and a higher value in the MG63 cell line. 
Moreover, because of the silencing, we found that 
SERPINE-1, CXCL12 and HTATIP2 genes showed a 
modulation of gene expression values compared to before 
KMT2C mRNA silencing only in the Hs888 metastatic 
line; we found that the expression values of SERPINE-1 
and CXCL12 genes was decrease while we found an 
increase in the expression value of the HTATIP2 gene 
(Table 2). 
Figure 1: Histogram of the average percentage of cells that show nuclear and cytoplasmic positivity for KMT2C by 
immunohistochemical staining; (A) overall; (B) responder; (C) non-responder. 
Figure 2: Immunohistochemical KMT2C expressions in osteosarcoma performed on TMA spot (10× and 40×).
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Finally, the other 84 genes (84/92, 91.3%) did not 
show variations in expression levels after KMT2C mRNA 
silencing in all osteosarcoma cell lines.
DISCUSSION
KMT2C belongs to the family of histone-modifying 
proteins KMT2, it catalyses the monomethylation of H3K4 
[17] and recent studies provided significant data that bind 
dysregulation of genes coding chromatin-modifying and 
remodeling proteins to cancer [13]. The monomethylation 
of H3K4 occurs more frequently on enhancer regions 
[18]; so, it is possible that mutations in proteins like 
KMT2C could inactivate tumor suppressors or activate 
oncogenes [13]. Moreover, chromatin modifiers are 
already recognized as a cancer therapy target and clinical 
trials for the treatment of MLL1/KMT2A-fusion leukemia 
provide evidence for the development of drugs targeting 
the members of KMT2 family [19].
We found that most of analysed osteosarcoma 
samples (97%) showed both nuclear and cytoplasmic 
immunohistochemical expression of KMT2C and the 
percentage of cytoplasmic positive cells was higher 
than the percentage of nuclear positive cells. Moreover, 
the cellular localization of KMT2C, both nuclear and 
cytoplasmic, was confirmed by immunofluorescence 
analysis. The nuclear localization of KMT2C agrees with 
its function as co-activator of transcriptional factors while 
the cytoplasmic localization, that was already described 
for KMT2C [20], showed that there was an altered 
intracellular localization of KMT2C (nuclear-cytoplamic 
trafficking). Recent evidence shows that specific variations 
Table 1: Results of KMT2C immunohistochemical analysis and KMT2C gene expression analysis







Overall 32 8.9* 38.6* *p < 0.0001
High grade osteosarcoma 
(NOS) 23 11.1 38.9 5.4
Parosteal osteosarcoma 3 3.7 33.0 3.2
Central low-grade osteosarcoma 3 4.0 26.3 2.2
Telangiectatic osteosarcoma 2 3.0 66.5 3.6
Periosteal osteosarcoma 1 1.0 30.0 1.1  
Responder 13 4.9* 39.8* 4.7 *p < 0.0001
Non-Responder 11 12.9* 39.4* 5.4 *p = 0.0073
G1–G2 9 4.3 26.6 2.2
G3–G4 23 10.5 42.6 5.5  
Overall metastasis 3 7.0 54.0 5.8
Pulmonary metastasis 1 15.0 68.0 2.0
Bone metastasis 2 3.0 47.0 7.7  
Relapse 4 2.5 26.2 2.7  
The IHC values are expressed as percentage of tumor cells with nuclear and cytoplasmic positivity.
Figure 3: Immunofluorescence staining with KMT2C antibody in Saos-2 osteosarcoma cell line (40×). 
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of KMT2C can lead to different effects, including the 
inactivation of the protein or a change in the enzymatic 
activity [21]. The cytoplasmic localization of KMT2C 
could likely lead to a loss, gain, or change in its function 
supporting osteosarcoma tumorigenesis. Moreover, the 
only one sample that did not show the nuclear localization 
of the protein showed the highest value of KMT2C mRNA 
expression. Since this is an isolated case, we could 
speculate that the protein not present at the nuclear level 
cannot perform its canonical function, and this leads to an 
increase of the transcription of the KMT2C gene.
Even if we did not find a statistically significant 
difference between primary and metastatic tumors, we 
observed that between low grade primary tumor and 
high grade primary tumor there was an increase of the 
percentage of cells with nuclear positivity while this 
value decreased in metastatic tissues. On the contrary, the 
KMT2C gene expression value as well as the percentage 
of cells with cytoplasmic positivity increased from low 
grade primary tissue to metastatic tissues. This observation 
could corroborate our hypothesis that the cytoplasmic 
localization of KMT2C probably determined a change in 
its function even during metastatic progression.
After KMT2C mRNA silencing, we observed that 
CD44 and FN1 underwent a modulation of their values. 
CD44, a trans-membrane glycoprotein, communicates 
with the cytoskeleton through its cytoplasmic domain 
[22]. The association between CD44 expression and tumor 
biology of osteosarcoma is known [23]. FN1 encodes 
fibronectin, which may be present in dimeric or multimeric 
form at the cell surface and in the Extracellular Matrix 
(ECM) [24]. It is involved in cell adhesion, migration and 
metastasis and association between fibronectin expression 
and invasiveness has been documented in several tumors 
[12]. Our data highlighted that KMT2C modulated the 
gene expression of CD44 and FN1 probably influencing 
the attachment of osteosarcoma cells to ECM, a necessary 
step for osteosarcoma cells to metastasize [25]. 
Coherently with other studies carried out on 
osteosarcoma cell lines, we observed that MMP2 was 
upregulated in all osteosarcoma cell lines [26] especially 
in metastatic cell line. MMPs are proteolytic enzymes 
that tightly control the degradation of ECM [27] and their 
altered expression was correlated with poor prognosis in 
different human cancers [28], including osteosarcomas 
[26]. Regulation of MMPs is linked to tissue inhibitor of 
MMPs (TIMP) and their action determines the inhibition 
of cell invasion [28]. According to a recent study [29], 
we observed a negative correlation between MMP2 and 
TIMP1 and after KMT2C mRNA silencing we found 
an increase of MMP2 gene expression value in all cell 
lines and a decrease of TIMP1 expression values in 
Figure 4: The mRNA expression level of KMT2C detected by real-time PCR before (T0), 24 and 48 hours after KMT2C siRNA 
transfection in 143B (A), MG63 (B), Hs888 (C) and Saos-2 (D) osteosarcoma cell lines.
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primary osteosarcoma cell lines while in metastatic cell 
line remained constant. Therefore, our study shows that 
KMT2C could be involved in ECM modifications that lead 
to metastatic progression and it could regulate the MMP2 
activity in osteosarcoma progression.
Surprisingly, we observed that two cell lines, 
particularly the metastatic cell line Hs888, showed an 
upregulation of gene codifying α-CATENIN (CTNNA1) 
and after KMT2C mRNA silencing the gene expression 
value of CTNNA1 decreased only in metastatic cell line. 
α-CATENIN is recognized as a putative tumor suppressor 
both in maintenance of cell-cell adhesion and regulating 
β-CATENIN activity in the Wnt/β-catenin pathway 
[30], also involved in osteosarcoma carcinogenesis 
[31]. Our data highlighted that α-CATENIN is expressed 
in osteosarcoma cell lines and we could argue that 
α-CATENIN expression values could decrease only during 
metastasis development in osteosarcoma and that this 
process could be regulated by KMT2C. 
From gene expression analysis we found that 
three genes (CXCL12, SERPINE1, HTATIP2) were 
upregulated only in metastatic cell line and that these 
values were modulated after KMT2C mRNA silencing. 
Particularly, we found that the CXCL12 gene expression 
decreased after KMT2C mRNA silencing. Chemokine 12 
is a chemoattractive cytokine involved in the metastasis 
process in some cancer, and the binding to its receptor 
leads to the activation of several downstream pathways 
that regulate survival, proliferation and migration [32]. 
Recently, the chemokine CXCL12/CXCR4 signaling 
has been extensively investigated in osteosarcoma due 
to the relevance in metastasis progression and poor 
patient outcome [33]. In addition, it has been showed that 
the CXCL12-CXCR4 axis activation leads to increase 
of metalloproteinase expression, as MMP2, causing 
degradation of ECM at the invasion front [34]. Coherent 
with this data we found that MMP2 gene expression 
level was higher in metastatic cell line than the other 
osteosarcoma cell lines. So, as in other types of tumors 
[33], the use of small molecule antagonists of this 
chemokine receptors may be useful to interfere with tumor 
progression and metastasis in osteosarcoma patients.
Glycoprotein SERPINE1 (PAI-1) has been shown 
to be involved in promoting cell adhesion and a higher 
expression of SERPINE1 in tumor cells contributes to 
cancer progression including metastasis [35]. In human 
osteosarcoma cells its expression is correlated with 
an increased risk of lung metastasis [36]. In line with 
literature, through our study we found that this gene was 
upregulated only in osteosarcoma metastatic cell line and 
after KMT2C mRNA silencing, we observed a decrease 
of gene expression value. Given that the mechanism by 
which SERPINE1 promotes the invasion and metastasis of 
osteosarcoma cells remains unknown [36], following our 
Table 2: Gene expression values of the 8 genes that showed different expression levels before and after (bold) mRNA 
KMT2C silencing in Osteosarcoma (OS) cell lines
GENE OS primary cell lines OS metastatic cell line
143B MG63 Saos-2 Hs888
FN1 23.6 3.0 3.2 71.8
FN1 30.6 3.41 1.9 64.1
CD44 640.9 21.9 0.3 23.7
CD44 5.8 16.6 0.6 36.1
MMP2 1 11.5 4.0 19.5
MMP2 1.9 20.5 6.9 24.8
TIMP1 5.0 1.3 1.9 14.0
TIMP1 3.7 1.0 1.1 14.0
CTNNA1 0.7 1.8 0.9 3.1
CTNNA1 0.8 2.6 0.7 2.2
CXCL12 0.0 0.0 0.0 11.3
CXCL12 0.0 0.0 0.0 6.6
SERPINE1 0.0 0.0 0.0 15.0
SERPINE1 0.0 0.0 0.0 9.4
HTATIP2 0.0 0.0 0.0 1.4
HTATIP2 0.0 0.0 0.0 3.1
Oncotarget30630www.oncotarget.com
analysis, we hypothesize a role of KMT2C in this process. 
Therefore, it would be interesting to deepen the knowledge 
of the role of SERPINE1 in osteosarcoma progression 
to obtain a marker for the prediction of metastasis 
development. Finally, we observed that gene HTATIP2, 
which codifies a metastasis suppressive protein, was 
upregulated only in metastatic cell line and after KMT2C 
mRNA silencing we observed an increase of the gene 
expression value. HTATIP2 is involved in the control of 
cell apoptosis, growth, metastasis, angiogenesis and DNA 
repair; it has been found to be expressed in different tumors 
[37–38], but it has never been described in osteosarcoma. 
For these reasons, it would be interesting to study the 
possible involvement of this protein in osteosarcoma 
progression.
In conclusion, we obtained valuable information 
about KMT2C in osteosarcoma: we found a nuclear-
cytoplasmic trafficking that could have a role in 
osteosarcoma carcinogenesis and progression probably 
linked to the consequent change of its function. Our 
hypothesis is that KMT2C affecting negatively or 
positively the enhancer activity of genes involved in 
osteosarcoma progression, it could play a role of oncogene 
or oncosuppressor, particularly in the degradation and 
attachment of tumor cells to ECM. However, further 
studies are needed to better understand the role of KMT2C 
in osteosarcoma carcinogenesis and progression because 
epigenetic therapy is promising for cancer treatment in the 
light of recent developments in this field. Therefore, this 
study could offer the opportunity to identify a potential 
therapeutic target to obtain personalized therapy and 
increase the survival rate of young patients affected by 
osteosarcoma.
MATERIALS AND METHODS
Population of study 
The population of this study included 32 patients 
with osteosarcoma from the files of the Department of 
Medical and Surgical Sciences and Biotechnologies, 
Sapienza University of Rome, Latina, Italy. The 
patients, informed during the follow-up, gave their 
consent for the study. The WHO 2013 classification of 
bone tumors was used to classify the bone lesions. The 
clinical-pathological features are described in Table 3. 
Patients had a mean follow-up time of 9.5 years (range 
1–18 years). Out of these 24 patients who received 
neoadiuvant chemotherapy, 13 (identified as “responder”, 
54%) didn’t develop metastasis, while 11 patients 
(identified as “non-responder”, 46%) did not respond 
to neoadjuvant chemotherapy, developed metastasis 
and died. Two patients had histologically proven bone 
metastases at diagnosis and for one patient we had the 
tissue of pulmonary metastasis. Moreover, for 4 patients 
we collected relapse tissue. There were no instances of 
inherited cancer predisposition syndromes associated with 
osteosarcoma among our samples. A bone tissue sample of 
patient with diagnosis of osteoporosis was used as control 
for gene expression analysis. All the tissue samples were 
reviewed on microscopy examinations by two dedicated 
pathologists. 
Immunohistochemical analysis of KMT2C
TMA sections (2 μm), of osteosarcoma 
samples, already used for other our studies [39], were 
deparaffinized and rehydrated in graded ethanol. 
Endogenous peroxidase activity was blocked by 3% 
hydrogen peroxide for 10 minutes. Antigen retrieval was 
performed in EDTA (pH 8.0) for 15 minutes. Blocking not 
specific sites was performed with Protein Block Serum-
Free (DAKO, Carpinteria, CA, USA). The tissue sections 
were then incubated with goat IgG polyclonal antibody 
anti-MLL3 (Q-20, Santa Cruz Biotechnology, Dallas, 
TX, USA) 1:50, at 4° C overnight. After incubation, 
specimens were washed with TBS buffer and with the 
secondary biotinylated antibody and subsequently with 
the streptavidin–biotin–peroxidase (DAKO LSAB Kit 
peroxidase; DAKO, Carpinteria, CA, USA). The samples 
were then washed with TBS buffer and incubated with 
freshly prepared DAB + substrate–chromogen buffer 
at room temperature. After gently rinsing with ddH2O, 
slides were counterstained with hematoxylin and mounted 
with permanent mounting media. Both positive and 
negative internal and external controls were used in each 
experiment. The immunostaining was evaluated by two 
experienced blinded pathologists using a double score 
based on staining localization (cytoplasmic/nuclear) 
and on the percentage of positive neoplastic cells. The 
percentage of positive neoplastic cells for each sample was 
calculated as the average of the positive neoplastic cells of 
the three TMA spot. 
GENE expression analysis – RealTime PCR 
Total RNA from Formalin-Fixed Paraffin 
Embedded (FFPE) samples was extracted using 
RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE 
(ThermoFisher Scientific, Waltham, MA, USA) according 
to the manufacturer’s instructions. We confirmed the 
purity and quantity of RNA by NanoDrop ND-1000 
Spectrophotometer (ThermoFisher Scientific, Waltham, 
MA, USA). The RNA was reverse transcribed into 
cDNA with High-Capacity cDNA Reverse Transcription 
Kit (Thermo Fisher Scientific, Waltham, MA, USA). 
PCR product of human KMT2C (Gene ID: 58508, 
Hs01005521_m1, ThermoFisher Scientific, Waltham, MA, 
USA) was detected using gene-specific primer and probe 
labeled with reporter dye FAM, which yielded a predicted 
amplicon of 58 bp. β-ACTIN (Gene ID: 60, Hs01060665_
g1, ThermoFisher Scientific, Waltham, MA, USA) was 
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used as an internal standard, which yielded a predicted 
amplicon of 171 bp. TaqMan real-time quantitative PCR 
for KMT2C mRNA was performed on an ABI PRISM 
7500 Fast Real-Time PCR System (Applied Biosystem, 
Foster City, CA, USA). PCR reaction was carried out in 
triplicate on 96-well plate with 10 uL per well using 1X 
TaqMan Master Mix. After an incubation for 2 minutes at 
50° C and 10 minutes at 95° C, the reactions continue for 
40 cycles at 95° C for 15 seconds and 60° C for 1 minute. 
At the end of the reaction, the results were evaluated 
using the ABI PRISM 7500 software (Applied Biosystem, 
Foster City, CA, USA). The cycle threshold (Ct) values for 
each set of 3 reactions were averaged for all subsequent 
calculations. The 2−ΔΔCt method was used to calculate 
relative changes in gene expression.
Cell culture
143B, MG63, Saos-2, and Hs888 human 
osteosarcoma cells lines obtained from American 
Type Culture Collection (ATCC, Manassas, VT, USA) 
were cultured in Dulbecco’s modified Eagle’s medium 
supplemented with 10% to 15% fetal bovine serum, 1mM 
sodium piruvate, 100 U/mL of penicillin, and 100 mg/mL 
of streptomycin, at 37° C and 5% CO2, according to 
ATCC recommendations. 143B, MG63 and Saos-2 were 
osteosarcoma primary cell lines while Hs888 was an 
osteosarcoma metastatic cell line (lung). All cell lines 
derived from young adults with osteosarcoma diagnosis, 
two males (MG63 and HS888) and two females (143B 
and Saos-2).





 9/32 28% ≤18 years
23/32 72% ≥18 years
Type of osteosarcoma
23/32 72% High grade osteosarcoma (NOS)
 3/32 9% Parosteal osteosarcoma
 3/32 9% Central low-grade osteosarcoma
 2/32 6% Telangiectatic osteosarcoma
 1/32 3% Periosteal osteosarcoma
*Grade
 9/32 28% G1–G2
23/32 72% G3–G4
Site of osteosarcoma
26/32 81% Upper limbs 
 2/32 6% Lower limbs
 3/32 9% Jaw/Mandible
 1/32 3% Lumbar vertebra
Stage
 4/32 12.5% IB
 5/32 15.5% IIA
21/32 66% IIB
 1/32 3% IVA
 1/32 3% IVB
Relapse
 4/32 12.5%  
*Sec. AJCC System.
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Immunofluorescence analysis of KMT2C
For immunofluorescent assay, the 143B, 
MG63, Saos-2 and Hs888 cells were fixed in a 4% 
paraformaldehyde solution for 5 minutes at 4° C and 
then cells were permeabilized with PBS + 0.01% Tween 
20 for 20 minutes at room temperature. Subsequently, the 
cells were incubated with goat IgG polyclonal antibody 
anti-MLL3 (Q-20, Santa Cruz Biotechnology, Dallas, 
TX, USA) 1:50, at 4° C overnight. The following day, 
cells were washed with PBS buffer + 0.01% Tween 20 
and subsequently cells were incubated with secondary 
antibody (Alexa Fluor 594 donkey anti-goat IgG; 
Invitrogen, Carlsbad, CA, USA) for 1 hour at room 
temperature. Then, the nuclei were counterstained with 
DAPI (Invitrogen, Carlsbad, CA, USA) for 10 minutes. 
Negative control was obtained by omitting the primary 
antibody. The fluorescence signal was examined with a 
fluorescence microscope Olympus IX50 with appropriate 
filters. Under 40X magnification, images of positive 
representative fields were captured.
KMT2C siRNA transfection
siRNA sequences targeting KMT2C and a negative 
control siRNA were designed and synthesized by 
Invitrogen (Life Technologies, Foster City, CA, USA). 
The siRNAs were designed according to the KMT2C 
complementary DNA (cDNA) sequence (Gene ID: 
58508). 143B, MG63, Saos-2, and Hs888 cells were 
seeded without antibiotics at 1/105 per well in 6-well 
plates 2 days before transfection. When cells were 90% 
confluent, the cells were washed with PBS and siRNAs 
were transfected into 143B, MG63, Saos-2 and Hs888 
cells using Lipofectamine RNAiMAX (Life Technologies, 
Foster City, CA, USA), according to the manufacturer’s 
instructions. The cells were harvested before and 24 and 
48 hours after transfection with KMT2C siRNA; then the 
cells were subjected to RealTime PCR to determine the 
mRNA expression of KMT2C. Total RNA was extracted 
with a SV Total RNA Isolation System (Promega, 
Madison, WI, USA), according to the manufacturer’s 
instructions. We confirmed the purity and quantity of 
RNA by NanoDrop ND-1000 Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA, USA). The RNA was 
reverse transcribed into cDNA with High-Capacity cDNA 
Reverse Transcription Kit (Thermo Fisher Scientific, 
Waltham, MA, USA). PCR products for human KMT2C 
and β-ACTIN, used as an internal standard, were detected 
using gene-specific primers and probes labeled with 
reporter dye FAM, which yielded a predicted amplicon 
of 58 and 171 bp, respectively. TaqMan RealTime 
quantitative PCR for KMT2C and β-ACTIN mRNA was 
performed on an ABI PRISM 7500 Fast Real-Time PCR 
System (Applied Biosystem, Foster City, CA, USA). PCR 
reaction was carried out in triplicate on 96-well plate 
with 10 uL per well using 1× TaqMan Master Mix. After 
an incubation for 2 minutes at 50° C and 10 minutes at 
95° C, the reactions continue for 40 cycles at 95° C for 
15 seconds and 60° C for 1 minute. At the end of the 
reaction, the results were evaluated using the ABI PRISM 
7500 software (Applied Biosystem, Foster City, CA, 
USA). The Ct values for each set of 3 reactions were 
averaged for all subsequent calculations. The 2-ΔΔCt method 
was used to calculate relative changes in gene expression.
Taqman array human tumor metastasis
Total RNA was extracted from harvested cells with a 
SV Total RNA Isolation System (Promega, Madison, WI, 
USA), according to the manufacturer’s instructions. We 
confirmed the purity and quantity of RNA by NanoDrop 
ND-1000 Spectrophotometer (Thermo Fisher Scientific 
Inc., Waltham, MA, USA).
The RNA was reverse transcribed into cDNA with 
highcapacity cDNA Reverse Transcription Kit (Thermo 
Fisher Scientific, Waltham, MA, USA). The cells were 
subjected to RealTime PCR to determine the mRNA 
expression of 92 gene involved in the metastatic pathway 
using TaqMan® Array 96-well Human Tumor Metastasis 
Plate (Applied Biosystem, Foster City, CA, USA) using 
10 uL per well using 5 uL of TaqMan Advanced Master 
Mix. Four housekeeping genes, GAPDH, HPRT1, GUSB 
and 18S, were used as internal controls. After UNG (Uracil 
N-Glycosylase) incubation of 2 minutes at 50° C and 
20 seconds of polymerase activation at 95° C, the reaction 
continues for 40 cycles at 95° C for 3 seconds and 60° C 
for 30 seconds. At the end of the reaction, the results were 
evaluated using the ABI PRISM 7500 software (Applied 
Biosystem, Foster City, CA, USA). The experiment was 
repeated in triplicate for each osteosarcoma cell line and 
the Ct values for each set of three reactions were averaged 
for all subsequent calculations. The 2−ΔΔCt method was used 
to calculate relative changes in gene expression.
Statistical analysis
Statistical analysis was performed using SPSS 
software (SPSS, Chicago, IL, USA). Comparison between 
parameters was calculated by paired and unpaired t-test. 
Correlations between variables were assessed by simple 
linear regression analysis. P value < 0.05 was considered 
statistically significant.
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